Gilead, Vertex initiated as new big biotech buys at Citi
Citi has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) at buy saying the former will benefit from short-term growth of Biktarvy (bictegravir, emtricitabine ...
Investor's Business Daily on MSN1h
Stock Market Today: Chevron Breaks Out, Disney Gets Some Of Its Mojo Back (Live Coverage)
Investors saw multiple shades of red in the stock market today. But some sectors showed strength. Beazer Homes broke out on earnings and ran past a new buy point of 35.20 in a seven-week base. Some ...
STAT10h
Vertex’s upcoming sciatica trial readout is a high-stakes moment in its quest to quell pain
VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.
News Medical15h
MaxCyte celebrates 25 years of innovation driving cell engineering-based therapeutics
MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...
MarketWatch22h
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...